Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 17, Issue 6, 2007, Pages 741-750

  Kronenberg, Sefi ^a,c   Apter, Alan ^a   Brent, David ^b   Schirman, Shella ^a   Melhem, Nadine ^b   Pick, Nimrod ^a   Gothelf, Doron ^a   Carmel, Miri ^a   Frisch, Amos ^a   Weizman, Abraham ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; SEROTONIN TRANSPORTER;

ADOLESCENT; ADULT; AGITATION; ANXIETY DISORDER; APPETITE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYPERSOMNIA; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MOTOR DYSFUNCTION; OPEN STUDY; OUTCOME ASSESSMENT; OUTPATIENT; PHARMACOGENETICS; RATING SCALE; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SUICIDE; SWEATING; TREATMENT RESPONSE; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY DISORDERS; CHILD; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; PSYCHOMETRICS; PSYCHOMOTOR AGITATION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEVERITY OF ILLNESS INDEX; SUICIDE; TREATMENT OUTCOME;

EID: 38549175154     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.0144     Document Type: Article

References (56)

1. Axelson DA, Perel JM, Birmaher B, Rudolph G, Nuss S, Yurasits L, Bridge J, Brent DA: Platelet serotonin re-uptake inhibition and response to SSRIs in depressed adolescents. Am J Psychiatry 162:802-804, 2005.
2. Anderson GM, Cook EH: Pharmacogenetics: Promise and potential in child and adolescent psychiatry. Child Adolesc Psychiatr Clin North Am 9:23-42, 2000.
3. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T: UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9:845-847, 1998.
4. Bernstein GA, Shaw K: Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 36:69S-84S, 1997.
5. Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, Neer SM: The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 36:545-553, 1997.
6. Birmaher B, Brent DA, Benson RS: Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37:1234-1238, 1998.
7. Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M: Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): A replication study. J Am Acad Child Adolesc Psychiatry 38:1230-1236, 1999.
8. Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, Bridge J, Heo J, Brent DA: Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 42:415-423, 2003.
9. Bondy B, Buettner A, Zill P: Genetics of suicide. Mol Psychiatry 11:336-351, 2006.
10. Bridge JA, Salary CB, Birmaher B, Asare AG, Brent DA: The risks and benefits of antidepressant treatment for youth depression. Ann Med 37:404-412, 2005.
11. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: Moderation by a polymorphism in the 5HTT gene. Science 301:386-389, 2003.
12. Du L, Faludi G, Palkovits M, Demeter E, Bakish D, Lapierre Y, Sotonyi P, Hrdina P: Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol Psychiatry 46:196-201, 1999.
13. Emslie G, Rush JA, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents. Arch Gen Psychiatry 54:1031-1037, 1997.
14. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL: Fluoxetine in child and adolescent depression: Acute and maintenance treatment. Depression and Anxiety 7:32-39, 1998.
15. Emslie GJ, Mayes TL, Laptook RS, Batt M: Predictors of response to treatment in children and adolescents with mood disorders. Psychiatr Clin North Am 26:435-456, 2003.
16. Emslie GJ, Ryan ND, Wagner KD. Major depressive disorder in children and adolescents: Clinical trial design and antidepressant efficacy. J Clin Psychiatry 66 (Suppl 7):14-20, 2005.
17. Epperson CN, Anderson GM, McDougle CJ: Platelet serotonin in breast-feeding infants of mothers receiving sertraline. New Engl J Med 336:1189-1190, 1997.
18. Fergusson DM, Woodward LJ: Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry 59:225-231, 2002.
19. Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 43:1387-1396, 2004.
20. Greenberg BD, Tolliver TJ, Huang S, Li Q, Bengel D, Murphy DL: Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88:83-87, 1999.
21. Guy W: Clinical Global Improvement Scale. Assessment Manual of Psychopharmacology. Rockville (Maryland), National Institute of Mental Health 1976, p. 76
22. Hamilton JD, Bridge J: Outcome at 6 months for 50 adolescents with major depression treated in a health maintenance organization. J Am Acad Child Adolesc Psychiatry 38:1340-1346, 1999.
23. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621-2624, 1996.
24. Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL, Bertilsson L: Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 56:415-421, 2003.
25. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E: Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46:1072-1077, 2000.
26. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR, Kennedy MA: Age-dependent antidepressant pharmacogenomics: Polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 6:339-346, 2003.
27. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997.
28. Kendler KS, Kuhn J, Prescott CA: The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry 161:631-636, 2004.
29. Kendler KS, Kuhn JW, Vittum J, Prescott CA, Riley B: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: A replication. Arch Gen Psychiatry 62:529-535, 2005.
30. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, Carroll BJ: Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 11:215-219, 2000.
31. Kowatch RA, Carmody TJ, Emslie GJ, Rintelmann JW, Hughes CW, Rush AJ: Prediction of response to fluoxetine and placebo in children and adolescents with major depression: A hypothesis generating study. J Affect Disord 4:269-276, 1999.
32. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP: Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 61:734-742, 2007.
33. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy, DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. 274:1527-1531, 1996.
34. Lucki I, O'Leary OF: Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 65:11-24, 2004.
35. Mann JJ, Huang YY, Underwood MD, Kassir SA, Oppenheim S, Kelly T, Dwork AJ, and Arango V: A serotonin transporter gene promoter polymorphism (5HTTLPR) and prefrontal cortical binding in major depression in suicide. Arch Gen Psychiatry 57:729-738, 2000.
36. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J: Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 292:807-820, 2004.
37. Mazzanti C, Lappalainen J, Long JC, Bengel D, Naukkarinen H, Eggert M, Virkkunen M, Linnoila M, Goldman D: Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Arch Gen Psychiatry 55:936-940, 1998.
38. McDougle CJ, Epperson CN, Price LH, Gelernter, J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 3:270-273, 1998.
39. Nakamura M, Ueno S, Sano A, Tanabe H: The human serotonin transporter gene linked polymorphism (5HTTLPR) shows ten novel allelic variants. Mol Psychiatry 5:32-38, 2000.
40. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet R, Davis S, Kirshner M, Houck P, Stack JA, Reynolds III CF, Kupfer DJ: Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587-590, 2000.
41. Poznanski E, Freeman LN, Mokros HB: Children's Depression Rating Scale-Revised. Psychopharmacol Bull 21:979-989, 1985.
42. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T: Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 12:465-472, 2002.
43. Schur BC, Bjerke J, Nuwayhid N, Wong SH: Genotyping of cytochrome P450 2D6*3 and *4 mutations using conventional PCR. Clin Chim Acta 308:25-31, 2001.
44. Serretti A, Kato M, De Ronchi D, Kinoshita T: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12:247-257, 2007.
45. Shanee N, Apter A, Weizman A: Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Isr J Psychiatry Relat Sci 34:179-186, 1997.
46. Smeraldi E, Zanardi R, Benedetti F, DiBella D, Perez J, Catalano M: Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508-511, 1998.
47. Stamer UM, Bayerer B, Wolf S, Hoeft A, Stuber F: Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 48:1412-1417, 2002.
48. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK: Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 5:215-523, 1995.
49. Tanigawara Y, Kita T, Hirono M, Sakaeda T, Komada F, Okumura K: Identification of N-acetyltransferase 2 and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood. Ther Drug Monit 23:341-346, 2001.
50. U.S. Food and Drug Administration. Relationship between psychotropic drugs and pediatric suicidality. Accessed at http://www.fda.gov/ohrms/dockets/ ac/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf/.
51. U.S. Food and Drug Administration: FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards for Children Treated With Antidepressant Medications. October. 2004. Accessed at http://www.fda.gov/bbs/topics/news/2004/NEW01124. html/.
52. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, Gee M, Davy K, Machin A: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153-1162, 2004.
53. Williams TP, Miller BD: Pharmacologic management of anxiety disorders in children and adolescents. Curr Opin Pediatr 15:483-490, 2003.
54. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 26:383-386, 2002.
55. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E: Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 20:105-107, 2000.
56. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E: Factors affecting fluvoxamine antidepressant activity: Influence of pindolol and 5HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323-330, 2001.